Promising signals of effect in Annexin’s RVO-study

Annexin Pharmaceuticals AB today announces that an independent evaluation of potential signals of effect has been carried out in the company's Phase 2-study in retinal vein occlusion with the investigational new drug ANXV. Positive findings justify an extended follow-up period.

The release as fetched from its publisher. annexinpharma.com ↗